LONDON (AP) _ Myovant Sciences Ltd. (MYOV) on Tuesday reported a loss of $81.4 million in its fiscal fourth quarter.
On a per-share basis, the London-based company said it had a loss of 89 cents.
The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 99 cents per share.
The biopharmaceutical company posted revenue of $24.6 million in the period.
For the year, the company reported that its loss narrowed to $255.1 million, or $2.83 per share. Revenue was reported as $59.3 million.
Myovant Sciences shares have fallen 34% since the beginning of the year. The stock has risen 45% in the last 12 months.
The Associated Press